Aditxt Inc. (ADTX)vsNovartis AG ADR (NVS)
ADTX
Aditxt Inc.
$0.01
+5.45%
HEALTHCARE · Cap: $9.48M
NVS
Novartis AG ADR
$157.54
-1.83%
HEALTHCARE · Cap: $288.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 395348561% more annual revenue ($56.69B vs $14,340). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ADTX
Avoid33
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADTX.
Margin of Safety
-71.8%
Fair Value
$93.10
Current Price
$157.54
$64.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1094.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ADTX
The strongest argument for ADTX centers on Revenue Growth, Debt/Equity. Revenue growth of 1094.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : ADTX
The primary concerns for ADTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
ADTX profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
ADTX is growing revenue faster at 1094.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 33/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aditxt Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Aditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it at the forefront of immunology and the broader healthcare landscape.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?